Pa­tient death in piv­otal gene ther­a­py tri­al rat­tles Sarep­ta part­ner al­ready fac­ing clin­i­cal hold

A child with mu­copolysac­cha­ri­do­sis type II­IA (MPS II­IA) has died in Lyso­gene’s piv­otal tri­al for its lead gene ther­a­py, four months af­ter the FDA im­posed a clin­i­cal hold on the study for pos­si­ble safe­ty con­cerns.

The study was sup­posed to pave the path to­ward com­mer­cial­iza­tion by Sarep­ta, which inked a $125 mil­lion deal in 2018 to mar­ket the drug, LYS-SAF302, in the US and world­wide ex­cept Eu­rope.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER